Biosig cleared to test merimepodib plus remdesivir in COVID-19

US biotech BioSig Technologies’ subsidiary ViralClear has been cleared by the FDA to start a phase 2 trial of its antiviral drug merimepodib in patients who are severely ill with COVID-19.